Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Front Immunol. 2022 Nov 21;13:1021452. doi: 10.3389/fimmu.2022.1021452. eCollection 2022.
Ischemia-reperfusion (I/R) injury is a type of pathological injury that commonly arises in various diseases. Various forms of immune response are involved in the process of I/R injury. As a member of the B7 costimulatory molecule family, programmed death 1-ligand 1 (PD-L1) is an important target for immune regulation. Therefore, PD-L1 may be implicated in the regulation of I/R injury. This review briefly describes the immune response during I/R injury and how PD-L1 is involved in its regulation by focusing on findings from various I/R models. Despite the limited number of studies in this field of research, PD-L1 has shown sufficient potential as a clinical therapeutic target.
缺血再灌注（I/R）损伤是一种常见于各种疾病的病理损伤。各种形式的免疫反应都参与了 I/R 损伤的过程。程序性死亡配体 1（PD-L1）作为 B7 共刺激分子家族的一员，是免疫调节的重要靶点。因此，PD-L1 可能参与了 I/R 损伤的调节。本综述简要描述了 I/R 损伤过程中的免疫反应，以及 PD-L1 如何通过聚焦于各种 I/R 模型中的发现来参与其调节。尽管该研究领域的研究数量有限，但 PD-L1 已显示出作为临床治疗靶点的巨大潜力。
